Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations.

The FLT3-ITD (internal tandem duplication) mutant has been a promising target for acute myeloid leukemia (AML) drug discovery but is now facing the challenge of resistance due to point mutations. Herein, we have discovered a type II FLT3 inhibitor, . This inhibitor has shown highly potent inhibitory effects against FLT3-WT (IC = 2.1 nM) and FLT3-ITD (IC = 1.0 nM), tumor cells with the FLT3-ITD mutant such as MOLM-13 (IC = 0.98 nM) and MV4-11 (IC = 0.19 nM), as well as BaF3 cells associated with the FLT3-ITD mutant and point mutations like BaF3-FLT3-ITD-G697R (IC = 3.0 nM). Moreover, exhibited promising kinome selectivity against 310 kinases (S score (10) = 0.06). In studies, significantly suppressed the tumor growth in MV4-11 (50 mg/kg/d, TGI = 87.3%) and BaF3-FLT3-ITD-G697R (50 mg/kg/d, TGI = 60.0%) cell-inoculated allograft models. Our data suggested that might be a promising drug candidate for FLT3-ITD-positive AML.